Form 4 for DGX Quest Diagnostics
Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-14 · accession 0001022079-24-000035 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-16 | 2024-02-14 | DGX | GARDNER MARK A | SVP of Molecular Gen, Oncol | A - Grant | $0.00 | +2,250 | 5,055 | +80% | $0 |
| D | 2024-02-16 | 2024-02-14 | DGX | GARDNER MARK A | SVP of Molecular Gen, Oncol | A - Grant | $0.00 | +9,376 | 9,376 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-14 | A | A | 2,250 | $0.00 | 5,055 | D | — | — | (F1) Represents an award of restricted share units. |
| 2 | Derivative | Non-Qualifed Stock Option (right to buy) | 2024-02-14 | A | A | 9,376 | $0.00 | 9,376 | D | $127.81 · — to 2034-02-14 | 9,376 Common Stock | (F2) The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. |